Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. News
  7. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China's BioKangtai begins first shipment of AstraZeneca's COVID-19 shot

11/19/2021 | 03:54am EST
FILE PHOTO: A doctor shows vials of AstraZeneca's COVID-19 vaccine in his general practice facility, as the spread of the coronavirus disease (COVID-19) continues, in Vienna, Austria

BEIJING (Reuters) - AstraZeneca Plc's COVID-19 vaccine partner in China, Shenzhen Kangtai Biological Products (BioKangtai), has begun its first shipment of the shot, sending more than four million doses to Indonesia, BioKangtai said on Friday.

Including the first batch, BioKangtai plans to send over eight million doses of the China-made AstraZeneca shot, branded as KconecaVac, to Indonesia this month, Zhang Qian, general manager at BioKangtai's international affairs department, said in a video interview with local media.

BioKangtai has the right to manufacture the vaccine, and the right to sell it in mainland China, Indonesia and Pakistan.

The shot hasn't begun clinical trials in China, which AstraZeneca hoped to start last year before the application for local regulatory approval for the shot.

Shenzhen-based BioKangtai, which has its own COVID-19 vaccine approved by China, hasn't said why trials for the AstraZeneca shot have been delayed.

Western companies including AstraZeneca and BioNTech have partnered with Chinese firms to bring their shots to the country, but China has not allowed the use of any coronavirus vaccines developed and approved overseas.

BioKangtai said in February its facility dedicated to making the AstraZeneca shot was expected to reach an annual production capacity of 400 million doses. Its actual production rate remains unclear.

AstraZeneca has already shipped about 10 million doses of its COVID-19 vaccine to Indonesia as of October, according to Indonesia's health ministry. The southeast Asian country has also received the vaccine through the global vaccine sharing scheme COVAX.

(Reporting by Roxanne Liu and Ryan Woo; Additional reporting by Stanley Widianto in Jakarta; Editing by Mark Potter)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.79% 8705 Delayed Quote.1.06%
BIONTECH SE -9.05% 178.095 Delayed Quote.-23.97%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. -0.96% 49.69 End-of-day quote.1.53%
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. -1.62% 90.51 End-of-day quote.-8.15%
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
2021China accelerating research into COVID-19 shots targeting Omicron - state media
RE
2021Shenzhen Kangtai Biological Products Co., Ltd. Announces Export of Kangtai Adenovirus V..
CI
2021AstraZeneca's Chinese Distributor Sends First Vaccine Shipment To Indonesia
MT
2021China's BioKangtai begins first shipment of AstraZeneca's COVID-19 shot
RE
2021National Agency of Drug and Food Control Grants the Emergency Use Authorization for Cov..
CI
2021Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Nine Mo..
CI
2021Shenzhen Kangtai Biological Products Co., Ltd. Announces 2021 Interim Distribution Plan..
CI
2021Shenzhen Kangtai Biological Products Co., Ltd. Approves Interim Cash Dividend for the F..
CI
2021Shenzhen Kangtai Biological Products Co., Ltd. Announces Recombinant COVID-19 Vaccine (..
CI
2021Shenzhen Kangtai Biological Products Co., Ltd. Proposes Cash Dividend for the First Hal..
CI
More news
Financials
Sales 2021 4 157 M 654 M 654 M
Net income 2021 1 396 M 220 M 220 M
Net cash 2021 3 514 M 553 M 553 M
P/E ratio 2021 47,4x
Yield 2021 0,26%
Capitalization 62 183 M 9 795 M 9 789 M
EV / Sales 2021 14,1x
EV / Sales 2022 9,74x
Nbr of Employees 2 043
Free-Float 46,4%
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | 300601 | CNE100002Q33 | MarketScreener
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 90,51 CNY
Average target price 169,99 CNY
Spread / Average Target 87,8%
EPS Revisions
Managers and Directors
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors